Real-world disease-modifying therapy pathways from administrative claims data in patients with multiple sclerosis

被引：0
|
作者：
Robert J. Fox
Rina Mehta
Timothy Pham
Julie Park
Kathleen Wilson
Machaon Bonafede
机构：
[1] Mellen Center for Multiple Sclerosis,
[2] Cleveland Clinic,undefined
[3] Bristol Myers Squibb,undefined
[4] IBM Watson Health,undefined
来源：
BMC Neurology | / 22卷
关键词：
Treatment pathway; Sankey diagram; Treatment patterns; Administrative claims database;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Disease-Modifying Therapies (DMTs) in Pregnant and Lactating Women with Multiple Sclerosis: Analysis of Real-World Data from EudraVigilance Database
    Sportiello, Liberata
    Di Napoli, Raffaella
    Balzano, Nunzia
    Mascolo, Annamaria
    Ruggiero, Rosanna
    Di Costanzo, Luigi
    Monaco, Davida
    Maniscalco, Giorgia Teresa
    Capuano, Annalisa
    PHARMACEUTICALS, 2023, 16 (11)
  • [22] Disease-modifying therapy for multiple sclerosis
    Holmoy, Trygve
    Myhr, Kjell-Morten
    Bo, Lars
    Nygaard, Gro Owren
    TIDSSKRIFT FOR DEN NORSKE LAEGEFORENING, 2021, 141 (08) : 723 - 726
  • [23] Disease-modifying therapy for multiple sclerosis
    Klineova, Sylvia
    Mitiku, Nesanet
    Miller, Aaron E.
    FUTURE NEUROLOGY, 2015, 10 (03) : 253 - 279
  • [24] Real-world persistence and adherence of ofatumumab versus oral and injectable disease-modifying therapies in patients with multiple sclerosis
    Hersh, Carrie M.
    Gorritz, Magdaliz
    Chen, Chi-Chang
    Tuly, Rifat
    Gu, Yifan
    Gadkari, Abhijit
    Brown, Brandon
    Shao, Qiujun
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2024, 91
  • [25] Real-world cost of care and site of care in patients with multiple sclerosis initiating infused disease-modifying therapies
    Alvarez, Enrique
    Nair, Kavita V.
    Tan, Hiangkiat
    Rathi, Kapil
    Gabler, Nicole B.
    Maiese, Eric M.
    Deshpande, Chinmay
    Shao, Qiujun
    JOURNAL OF MEDICAL ECONOMICS, 2023, 26 (01) : 494 - 502
  • [26] Development of a composite, administrative claims-based measure of disease severity among patients with multiple sclerosis receiving disease-modifying drug therapy
    Locklear, J. C.
    Phillips, A. L.
    Frean, M.
    Menzin, J.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 420 - 421
  • [27] Real-World Assessment of Adherence and Persistence to Second-Line Disease-Modifying Therapies among Multiple Sclerosis Patients
    Halpern, Rachel
    Agarwal, Sonalee
    Borton, Leigh A.
    Babic, Tomislav
    NEUROLOGY, 2010, 74 (09) : A548 - A549
  • [28] A Real-World Study of Disease-Modifying Drug Treatment Patterns in US Patients with Multiple Sclerosis Newly Initiating Treatment
    Nicholas, Jacqueline
    Edwards, Natalie C.
    Harlow, Danielle
    Phillips, Amy
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 20 - 20
  • [29] Infections in patients with multiple sclerosis: Implications for disease-modifying therapy
    Celius, E. G.
    ACTA NEUROLOGICA SCANDINAVICA, 2017, 136 : 34 - 36
  • [30] Multiple sclerosis disease-modifying therapy and pregnancy
    Miller, Aaron E.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 (06) : 715 - 716
12345